Best Grants for Cancer Nonprofits in Puerto Rico

The Research Scholar Grants (RSG) by the American Cancer Society support independent researchers engaged in cancer-related studies. Eligible applicants must be affiliated with US academic institutions and have been appointed as independent faculty for less than ten years. Grants provide funding up to $215,000 annually for direct costs and allow for 10% indirect costs, with project durations of up to four years, fostering innovative cancer research across various priority areas.

The ACS Professor Award, presented by the American Cancer Society, recognizes full professors who have significantly advanced cancer research. This honorific award aims to support innovative pursuits in cancer research with a budget of up to $80,000 per year for five years. Applicants are expected to demonstrate impactful contributions and leadership in the field, along with a commitment to mentorship and community engagement. The award highlights the importance of ongoing advocacy and research in improving cancer treatment and prevention.

The National Cancer Institute (NCI) invites applications for transformative research in cancer biology and oncology through nanotechnology. This funding opportunity aims to address significant challenges by exploring the interactions of nanomaterials with biological systems. Projects should focus on utilizing nanoparticles and devices for targeted cancer therapies and enhancing diagnostic capabilities. Successful proposals will contribute to the foundational knowledge necessary for future nanotechnology-based interventions in cancer treatment.

The Mission Boost Grants (MBG) by the American Cancer Society aim to enhance cancer research by funding projects that translate into human testing. These grants support investigators at all levels, offering resources for innovative clinical projects. The program consists of two funding stages: Stage I focuses on developing clear milestones for new treatments, while Stage II supports patient testing, ultimately contributing to advancements in cancer care and treatment.

The American Cancer Society's Mentored Research Grants for Postdoctoral Fellowships (PF) aim to support emerging researchers in their training programs, fostering their transition to independent cancer research careers. Eligible candidates include US citizens or non-citizens with valid visas who have completed their doctoral degrees within the last four years. The fellowship offers funding for up to three years, with stipends of $66,000 to $70,000 annually, alongside allowances for health insurance and professional development.

The Clinician Scientist Development Grant (CSDG) by the American Cancer Society supports full-time faculty aiming to become independent clinician scientists while maintaining clinical practice. Eligible applicants must hold a doctoral degree, an active clinical license, and have clinical care experience. The grant provides funding of $135,000 annually for 3 to 5 years, including allowable indirect costs, to advance cancer research in key priority areas.

The American Cancer Society (ACS) and the American Society for Radiation Oncology (ASTRO) co-fund the Clinician Scientist Development Grant (CSDG), aimed at advancing the research careers of clinician scientists in radiation oncology. Eligible applicants are full-time faculty members at U.S. institutions with a doctoral degree and an active clinical license. The grant supports research for 3 to 5 years, providing $135,000 annually for direct costs, plus allowable indirect costs, while encouraging diversity in applications.

The Institutional Research Grants (IRG) program by the American Cancer Society provides essential seed funding for newly independent investigators to launch cancer research projects. Aimed at junior faculty, these grants offer $120,000 annually for three years, supporting the development of preliminary results necessary for competing for larger national grants. Eligible applicants must be at US academic institutions and hold the rank of Associate or Full Professor, with a proven track record in research and mentorship.

The Cancer Research Education Grants Program (R25) aims to enhance research education in areas crucial to the NIH mission. This program supports innovative courses that develop skills in cancer research, covering topics such as prevention, diagnosis, and treatment. Grant applications are encouraged to be creative and state-of-the-art, addressing the needs of patients and their families. Key deadlines for applications span from January 2024 to September 2026, ensuring ongoing support for educational initiatives.

The Exploratory Grant Award aims to enhance workforce diversity in basic cancer research by supporting junior and Early Stage Investigators from underrepresented groups in the biomedical and social sciences. This initiative provides essential funding to bridge the gap for researchers completing their training, ensuring they have the resources needed to develop larger grant applications. Applications are due by 5:00 PM local time of the applicant organization, emphasizing the importance of timely submissions.

The National Cancer Institute invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation of assays, emphasizing the importance of human samples. The program encourages multi-disciplinary collaboration and aims to enhance the performance and reproducibility of cancer assays across clinical laboratories. Applications are due by 5:00 PM local time during the designated deadlines each year.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers aiming to transition to independent faculty positions. It encourages candidates with doctoral degrees in research or clinical fields to apply, particularly those in cancer control and prevention. This funding opportunity facilitates a quick shift from mentored research to independent careers, providing essential support for awardees to establish competitive research programs without leading their own clinical trials.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers transitioning to independent faculty positions. This funding opportunity encourages talented individuals with clinical or research doctoral degrees to lead independent clinical trials. Applicants should aim to foster research careers in cancer control, prevention, and data sciences. This initiative provides essential support during the transition from mentored positions to independent research roles, enhancing the pool of independent investigators in cancer research.

The NCI Worta McCaskill-Stevens Career Development Award supports new clinicians committed to research in community oncology and cancer prevention. This funding aims to facilitate their transition to independent research careers and advanced funding mechanisms. Scholars can lead independent community-based clinical trials, conduct ancillary studies, or gain valuable research experience, specifically targeting underserved communities. Applications are due by 5:00 PM local time of the applicant's organization.

The National Cancer Institute (NCI) is seeking applications for studies that explore how bariatric surgery influences cancer risk, emphasizing the need for innovative research in this area. This funding opportunity encourages the participation of researchers who focus on the long-term impacts of bariatric surgery beyond weight loss and diabetes, addressing critical gaps in understanding the disease mechanisms involved. Key deadlines for application submissions span from February 2025 to October 2027.

The National Cancer Institute (NCI) invites applications for studies on mechanisms by which bariatric surgery influences cancer risk. This funding opportunity encourages exploration beyond short-term outcomes like weight loss and diabetes. The goal is to support innovative proof of concept studies, emphasizing feasibility without prior development in the literature. Unpublished data is not allowed, but references from preprints with a DOI are acceptable. Deadlines for applications span from February 2025 to November 2027.

The National Cancer Institute (NCI) seeks to enhance the validation of biomarkers and assays for cancer detection and treatment through its UH3 funding mechanism. This initiative supports multi-disciplinary collaborations to validate existing assays over three years using clinical trial specimens. Emphasis is placed on harmonizing laboratory tests and validating pharmacodynamic markers. Projects should not focus on early-stage technology development but aim for integration into clinical studies as investigational assays.

The National Cancer Institute (NCI) invites applications for the validation of molecular, cellular, and imaging markers for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation phases, emphasizing multi-disciplinary collaboration. The UH2 phase focuses on analytical validation, while the UH3 phase extends to clinical validation using well-annotated biospecimens. Proposals should justify the relevance of assays for clinical use and may include harmonization efforts across laboratories.

The Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) aims to enhance cancer treatment by integrating imaging and liquid biopsy assays. This initiative, led by the National Cancer Institute (NCI), encourages grant applications focused on assessing therapy responses and resistance emergence in patients. Key deadlines for submissions span from February 2025 to January 2028, providing ample opportunities for researchers to contribute to this vital area of cancer research.

This funding opportunity invites applications for R01 grants focused on molecular imaging methods to explore cancer inflammation in vivo. It aims to enhance understanding of dynamic interactions between inflammation and cancer through innovative imaging techniques. The initiative encourages collaborations between cancer researchers and imaging scientists to leverage molecular imaging for identifying cellular physiology changes in response to treatment. Deadline dates for applications range from February 2025 to October 2027, emphasizing timely submission for prospective researchers.

The Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional) aims to fund projects that explore policies related to tobacco, alcohol, and cannabis in the U.S. The focus is on understanding how these policies affect usage and exposure among disadvantaged populations. Engaging community organizations is essential for promoting equity in cancer prevention. This initiative is crucial for advancing health equity and reducing disparities in substance use.

The Tobacco, Alcohol, and Cannabis Policy Research for Health Equity grant aims to support research on policies affecting tobacco, alcohol, and cannabis use in the U.S. This initiative focuses on how these policies impact populations facing health disparities. Key components include engaging community organizations to advance equity in cancer prevention. Important deadlines for applications range from February 2025 to October 2027, providing opportunities for both standard and renewal submissions.

The Academic Research Enhancement Award (AREA) supports small-scale research grants for institutions with limited NIH funding, emphasizing biomedical research experiences for undergraduates. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million in NIH support over the past seven years. This initiative aims to enhance the research environment at these institutions, fostering student involvement in research activities.

The NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22) supports early-career independent researchers to transition from postdoctoral positions to assistant professor roles. This award aims to enhance diversity in the biomedical workforce, offering funding opportunities for innovative research projects. Key application deadlines span from February 2025 to October 2027. The program is funded by the US Department of Health & Human Services, specifically the National Institutes of Health (NIH).

The National Cancer Institute (NCI) invites applications for the Toward Translation of Nanotechnology Cancer Interventions (TTNCI) program. This funding opportunity focuses on advanced pre-clinical research aimed at developing nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards will support the maturation of innovative nanomedicines using nanoparticles and nano-devices, enhancing cancer treatment efficacy. Successful projects will progress towards further NCI translational programs, such as the NExT initiative.

The FY26 Peer Reviewed Cancer Research Program Impact Award promotes significant research aimed at enhancing clinical cancer care. It requires preliminary data to ensure feasibility and emphasizes projects with a strong potential for immediate impact. This funding supports clinical trials and allows for either a single Principal Investigator or a duo of partnering PIs, ensuring that both can contribute distinct aspects of the research. Applications must be carefully coordinated to avoid withdrawal risks.

The Cancer Center Support Grants (CCSGs) aim to bolster NCI-Designated Cancer Centers through funding that supports diverse research activities. These grants enhance comprehensive, clinical, and basic cancer research while fostering collaboration among institutions. The program prioritizes interdisciplinary approaches to advance cancer prevention, diagnosis, and treatment, ultimately reducing cancer's impact on public health. CCSGs also facilitate resource sharing, administrative support, and the development of innovative research initiatives.